Antimalarial drug resistance: A global threat to malaria control?

Guest lecture by professor Philippe Guérin, University of Oxford, UK.

Philippe Guérin is the Director of the WorldWide Antimalarial Resistance Network (WWARN), appointed at its inception in 2009. He is Professor of Epidemiology and Global Health at the University of Oxford, UK. 

After working as a physician in France and Nepal, Philippe joined Médecins Sans Frontières (MSF) where he gained extensive experience of working in the field in several countries in Central Africa, Mali and as a researcher in Asia working on malaria and tuberculosis. Before moving to WWARN he spent six years as the Scientific Director of Epicentre in Paris, a WHO Collaborating Centre for Research in Epidemiology and Response to Emerging Diseases. Prior to this he also spent three years as a Senior Advisor at the Norwegian Institute of Public Health. Guérin has a medical degree, specialised in public health, an MPH and a PhD in Epidemiology.

WWARN is a scientifically independent multi-disciplinary collaborative resource generating innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. WWARN has pioneered the development of a platform to facilitate the sharing of individual patient data from antimalarial clinical trials, and now holds around two-thirds of the ACT efficacy data from around the world. The Network currently comprises of 255 collaborating organisations worldwide. WWARN is now piloting its innovative data-sharing model on some neglected tropical diseases such as schistosomiasis and visceral leishmaniasis.

Organizer

Pharma-Safe
Published Oct. 28, 2015 11:49 AM - Last modified Feb. 3, 2016 2:48 PM